Your browser doesn't support javascript.
loading
CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment.
Muthana, Musleh M; Du, Xuexiang; Liu, Mingyue; Wang, Xu; Wu, Wei; Ai, Chunxia; Su, Lishan; Zheng, Pan; Liu, Yang.
Affiliation
  • Muthana MM; Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States.
  • Du X; Department of Pharmacology, University of Maryland School of Medicine, Baltimore, United States.
  • Liu M; Key Laboratory of Infection and Immunity of Shandong Province & Department of Immunology, School of Basic Medical Sciences, Shandong University, Jinan, China.
  • Wang X; Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States.
  • Wu W; Department of Pharmacology, University of Maryland School of Medicine, Baltimore, United States.
  • Ai C; Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States.
  • Su L; Department of Pharmacology, University of Maryland School of Medicine, Baltimore, United States.
  • Zheng P; OncoC4, Inc, Rockville, United States.
  • Liu Y; Key Laboratory of Infection and Immunity of Shandong Province & Department of Immunology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Elife ; 122023 Dec 21.
Article in En | MEDLINE | ID: mdl-38127423
ABSTRACT
Germline CTLA-4 deficiency causes severe autoimmune diseases characterized by dysregulation of Foxp3+ Tregs, hyper-activation of effector memory T cells, and variable forms autoimmune cytopenia including gradual loss of B cells. Cancer patients with severe immune-related adverse events (irAE) after receiving anti-CTLA-4/PD-1 combination immunotherapy also have markedly reduced peripheral B cells. The immunological basis for B cell loss remains unexplained. Here, we probe the decline of B cells in human CTLA-4 knock-in mice by using anti-human CTLA-4 antibody Ipilimumab conjugated to a drug payload emtansine (Anti-CTLA-4 ADC). The anti-CTLA-4 ADC-treated mice have T cell hyper-proliferation and their differentiation into effector cells which results in B cell depletion. B cell depletion is mediated by both CD4 and CD8 T cells and at least partially rescued by anti-TNF-alpha antibody. These data revealed an unexpected antagonism between T and B cells and the importance of regulatory T cells in preserving B cells.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: B-Lymphocytes / T-Lymphocytes, Regulatory / Abatacept Limits: Animals Language: En Journal: Elife Year: 2023 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: B-Lymphocytes / T-Lymphocytes, Regulatory / Abatacept Limits: Animals Language: En Journal: Elife Year: 2023 Document type: Article Affiliation country: Country of publication: